Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below Fifty Day Moving Average - Should You Sell?

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $18.71 and traded as low as $17.63. Seres Therapeutics shares last traded at $18.16, with a volume of 72,790 shares traded.

Analysts Set New Price Targets

Several analysts recently issued reports on MCRB shares. Canaccord Genuity Group upped their target price on Seres Therapeutics from $14.00 to $22.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Seres Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Seres Therapeutics has a consensus rating of "Reduce" and a consensus price target of $14.33.

Seres Therapeutics Price Performance

The business has a 50-day simple moving average of $18.71 and a two-hundred day simple moving average of $13.11. The stock has a market cap of $158.90 million, a price-to-earnings ratio of -3.95 and a beta of 0.19.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($2.27) earnings per share for the quarter, topping analysts' consensus estimates of ($2.72) by $0.45. As a group, equities analysts anticipate that Seres Therapeutics, Inc. will post -0.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Seres Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Vontobel Holding Ltd. increased its position in Seres Therapeutics by 15.7% during the first quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company's stock worth $760,000 after buying an additional 147,671 shares during the last quarter. Invesco Ltd. increased its position in Seres Therapeutics by 193.2% during the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock worth $96,000 after buying an additional 89,995 shares during the last quarter. Marshall Wace LLP acquired a new position in Seres Therapeutics during the second quarter worth approximately $1,016,000. Goldman Sachs Group Inc. increased its position in Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock worth $52,000 after buying an additional 21,679 shares during the last quarter. Finally, SBI Securities Co. Ltd. increased its stake in shares of Seres Therapeutics by 221.8% during the first quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 48,013 shares during the period. Institutional investors and hedge funds own 59.34% of the company's stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.